Response Genetics Company Description
For Response Genetics, the answer to cancer is in the genes. The life sciences company develops clinical diagnostic tests for cancer based on genetic analysis of tumor tissues. Results of these tests can predict a patient's response to chemotherapy, as well as the potential for cancer recurrence, and can help doctors determine the best course of treatment. Its two commercial ResponseDx products are sold to select medical institutions and test lung and colorectal cancer. Response Genetics makes most of its revenue by providing laboratory testing services on clinical trial specimens for the pharmaceutical industry in the US, Europe, and Japan. Customers include GlaxoSmithKline and Taiho Pharmaceutical.
View the Comprehensive Company Description for Response Genetics
The Company Description provides a historical perspective of Response Genetics's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Response Genetics's evolution in the marketplace.
